Schott Pharma stock holds steady as investors await next guidance

Schott Pharma AG & Co. KGaA (ISIN DE000A3ENQ51) stock is quoted at around EUR 23.45 on its home market Xetra as of September 20, 2026, only about 3 percent below the average analyst price target of EUR 24.13. According to FinanzNachrichten on September 20, 2026, twelve analysts currently rate Schott Pharma a buy, two a hold and none a sell.

Analysts see limited but positive upside

The latest analyst overview shows an average price target of EUR 24.13 for Schott Pharma, compared with a current Xetra price of about EUR 23.45 as of September 20, 2026, implying roughly 3 percent upside from the consensus view. According to FinanzNachrichten on September 20, 2026, twelve analysts recommend buying the stock and two suggest holding it, underlining that the majority of coverage still expects further gains.

For investors, this setup means the shares are already trading close to the level the analyst community considers fair value, but without signs of a broad downgrade cycle. The near alignment of price and target can make future guidance or contract wins more important as potential catalysts to push Schott Pharma stock meaningfully above the current range.

Packaging demand supports the pharma-focused business

Schott Pharma develops and supplies high-quality containers for injectable drugs, benefiting from structural growth in pharmaceutical packaging. As MarketsandMarkets reported in an industry study updated on August 25, 2026, Schott AG is a major producer of depyrogenated glass containers for injectables, and the broader injectable packaging market is expanding as pharmaceutical companies adopt ready-to-use formats to improve manufacturing outcomes and reduce contamination risks.

While the industry study focuses on the parent group Schott AG, it highlights the tailwind for Schott Pharma’s core business of vials, ampoules, cartridges and prefillable syringes used in injectable therapies. According to MarketsandMarkets, demand for such products is being driven by stricter endotoxin testing requirements and the need for depyrogenated glassware in advanced manufacturing environments.

Stock valuation and trading context

On valuation, a consensus target of EUR 24.13 compared with a Xetra price near EUR 23.45 as of September 20, 2026 shows that Schott Pharma stock is seen as modestly undervalued by analysts rather than deeply discounted. With twelve buy ratings versus just two hold recommendations in the same overview from FinanzNachrichten, the risk perception appears manageable, though any disappointment in future revenue or margin trends could quickly narrow that support.

As of September 20, 2026, Schott Pharma’s market capitalization can be inferred in the mid-single-digit billion-euro range from typical valuation levels at a share price around EUR 23.45, but detailed figures for the latest quarter or half year are awaited from the company’s investor-relations publications. For investors, the key question is whether upcoming communications on guidance or results at Schott Pharma will confirm the growth implied by the industry’s injectable packaging trends.

Schott Pharma stock price snapshot

Schott Pharma stock most recently traded at approximately EUR 23.45 on Xetra as of September 20, 2026, with the shares hovering close to the average analyst price target of EUR 24.13 and supported by twelve buy ratings and two hold ratings in the latest coverage overview. The combination of modest upside to consensus, steady recommendations and structural demand for injectable pharma packaging defines the current risk-reward profile for the stock.

More news and analyses on Schott Pharma stock